EUVIMEDEUVIMED entdecken
Crossref

High hyperdiploid karyotype with ≥ 49 chromosomes represents a heterogeneous subgroup of acute myeloid leukemia with differential TP53 mutation status and prognosis: a single-center study from China

Zhiyu Zhang, Chunmei Fu, Yingxin Sun, Yizi Liu, Qian Wang, Wanhui Yan, Chunxiao Wu, Qingrong Wang, Zhao Zeng, Lijun Wen, Hongjie Shen, Li Yao und 3 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05834-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Zhiyu Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suz…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Tumor Suppressor Protein p53, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Key Research and Development Program of China,China, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High hyperdiploid karyotype with ≥ 49 chromosomes (which will be referred to as HHK) is rare in acute myeloid leukemia (AML). The European leukemia network (ELN) excluded those harboring only numerical changes (with ≥ 3 chromosome gains) from CK and listed them in the intermediate risk group, while the UK National Cancer Research Institute Adult Leukaemia Working Group classification defined ≥ 4 unrelated chromosome abnormalities as the cutoff for a poorer prognosis. Controversies occurred among studies on the clinical outcome of HHK AML, and their molecular characteristics remained unstudied. We identified 1.31% (133/10,131) HHK cases within our center, among which 48 cases only had numerical changes (NUM), 42 had ELN defined adverse abnormalities (ADV) and 43 had other structural abnormalities (STR). Our study demonstrated that: (1) No statistical significance for overall survival (OS) was observed among three cytogenetic subgroups (NUM, STR and ADV) and HHK AML should be assigned to the adverse cytogenetic risk group. (2) The OS was significantly worse in HHK AML with ≥ 51 chromosomes compared with those with 49-50 chromosomes. (3) The clinical characteristics were similar between NUM and STR group compared to ADV group. The former two groups had higher white blood cell counts and blasts, lower platelet counts, and mutations associated with signaling, while the ADV group exhibited older age, higher chromosome counts, higher percentage of myelodysplastic syndrome (MDS) history, and a dominant TP53 mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteTumor Suppressor Protein p53MutationHumansMiddle AgedFemaleMaleAdultAgedChinaPrognosisAdolescentYoung AdultAged, 80 and overChromosome AberrationsKaryotypeSurvival RateKaryotyping

Stichwörter der Autor:innen

Acute myeloid leukemiaComplex karyotype, TP53High hyperdiploid karyotype

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China.
  • Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Department of Hematology, Xuzhou Central Hospital, 199 Quanshan District, Xuzhou, China.
  • Department of Hematology, Affiliated hospital of Nantong University, Nantong University, Nantong, China.
  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China. chensuning@sina.com.
  • Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. chensuning@sina.com.

Förderung

  • National Key Research and Development Program of China
  • National Key Research and Development Program of China,China
  • the National Natural Science Foundation of China

Zitieren

APA

Zhang, Z., Fu, C., Sun, Y., Liu, Y., Wang, Q., Yan, W., Wu, C., Wang, Q., Zeng, Z., Wen, L., Shen, H., Yao, L., Liu, D., Chen, S., & Pan, J. (2024). High hyperdiploid karyotype with ≥ 49 chromosomes represents a heterogeneous subgroup of acute myeloid leukemia with differential TP53 mutation status and prognosis: a single-center study from China. Annals of Hematology. https://doi.org/10.1007/s00277-024-05834-5

Vancouver

Zhang Z, Fu C, Sun Y, Liu Y, Wang Q, Yan W, et al. High hyperdiploid karyotype with ≥ 49 chromosomes represents a heterogeneous subgroup of acute myeloid leukemia with differential TP53 mutation status and prognosis: a single-center study from China. Annals of Hematology. 2024. doi:10.1007/s00277-024-05834-5

BibTeX
@article{Zhang2024,
  author = {Zhang, Zhiyu and Fu, Chunmei and Sun, Yingxin and Liu, Yizi and Wang, Qian and Yan, Wanhui and Wu, Chunxiao and Wang, Qingrong and Zeng, Zhao and Wen, Lijun and Shen, Hongjie and Yao, Li and Liu, Dandan and Chen, Suning and Pan, Jinlan},
  title = {High hyperdiploid karyotype with ≥ 49 chromosomes represents a heterogeneous subgroup of acute myeloid leukemia with differential TP53 mutation status and prognosis: a single-center study from China},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05834-5}
}
Kostenlos starten →